Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features

NCT04797299 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.

NCT NCT04797299
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04797299 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ Defined by a Molecular Expression Assay Combined With Clinico-Pathological Features
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Phase
Observational
Overall status
Active, not recruiting
Start date
November 23, 2022
Completion date
November 30, 2035
Enrollment
526 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

dcis